Alumkal, Joshi J <br/><br/>
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.  [electronic resource] 

 -  Clinical genitourinary cancer  10 2017 
 - 610-617.e3 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1938-0682 
<br/><br/><label>Standard No.: </label>10.1016/j.clgc.2017.02.007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Aged<br/>Aged, 80 and over<br/>Benzamides<br/>Double-Blind Method<br/>Humans<br/>Liver Neoplasms--drug therapy<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Nitriles<br/>Phenylthiohydantoin--administration & dosage<br/>Prognosis<br/>Prostatic Neoplasms, Castration-Resistant--drug therapy<br/>Treatment Outcome